Each vial contains 300 mg vedolizumab and after reconstitution, each ml contains 60 mg vedilizumab.


This drug is indicated in ulcerative colitis and Crohn’s disease in the adult.

Side effects

Mild to moderate side effect has been observed such as fatigue, respiratory tract infection, sinusitis


This drug is to be cautiously used in patients with liver disease, and progressive multifocal leukoencephalopathy.


This drug is contraindicated in patients with severe infection and ulcerative colitis.

Dosage and administration

In adults 300 mg injection is to be given intravenously in zero two and six weeks then every eight weeks.


We have also established roots and begun this new venture in other countries as well such as Japan, and U.A.E.

Available Forms